Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bayer, FUJIFILM RI Pharma Start Receiving Orders on Zevalin
August 25, 2008
- Market Price Surveys to Focus on Generics
August 25, 2008
- Pfizer Starts Detailing Macugen for AMD
August 25, 2008
- R&D NEWS IN BRIEF
August 25, 2008
- Top Management Changes Made within 2 Months Announced by Ono
August 25, 2008
- Development of New Drugs for AMD Stimulated
August 25, 2008
- Eisai Licenses Bendamustine from SymBio
August 25, 2008
- Long Lifecycles Prevent Quick Development of New Drugs in Japan: OPIR Report
August 25, 2008
- Eisai to Apply for 3 Anticancer Drugs by FY2012
August 25, 2008
- REGULATORY NEWS IN BRIEF
August 25, 2008
- DSP to Place Top Priority on Lurasidone: New President Tada
August 25, 2008
- Korosho Opposed to Reference Price System
August 25, 2008
- Uterocervical Cancer Vaccination Cuts Medical Spending by \43 Billion
August 25, 2008
- Risk Assessment Shows Acceptability of Raw Materials for Basiliximab, Alteplase
August 25, 2008
- Over 40% of Patients Could Stop Remicade for Over 1 Year
August 25, 2008
- More Research Centers in China
August 11, 2008
- Matsumotokiyoshi Acquires Mogi Pharmaceutical
August 11, 2008
- 9 Asian Studies Started in 2007
August 11, 2008
- Suzuken to Acquire a Dispensing Pharmacy Chain
August 11, 2008
- siRNA Therapeutic to Enter PI in 2009: GeneCare
August 11, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…